Aspergillus fumigatus is a saprotrophic fungus; its primary habitat is the soil. In its ecological
niche, the fungus has learned how to adapt and proliferate in hostile environments. This …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2
study assessed fedratinib in patients with intermediate‐or high‐risk myelofibrosis (MF) who …

Corticosteroid-refractory graft-versus-host disease (SR-GVHD) remains a significant source
of morbidity after allogeneic hematopoietic cell transplantation. No standard therapy exists in …

Tumor necrosis factor-alpha (TNF-a) is involved in the pathogenesis of several inflammatory
diseases such as rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, and …

Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …

Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …

Abstract Purpose of Review Small-molecule kinase inhibitors (SMKIs) have revolutionized
the management of malignant and autoimmune disorders. Emerging clinical reports point …

Simple Summary Polycythemia vera (PV) is a chronic blood disease characterized by
elevated red blood cells and splenomegaly. About 98% of all PV patients harbor the JAK2 …

BCR-ABL1-negative myeloproliferative neoplasms are burdened by a reduced life
expectancy mostly due to an increased risk of thrombo-hemorrhagic events, fibrotic …